Carregant...
Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience
INTRODUCTION: Several series of patient studies have been published on the use of rFVIIa in traumatic haemorrhagic shock, although to date no international recommendations have been produced. France does not currently recognise traumatic haemorrhagic shock as an appropriate indication for the use of...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Medknow Publications & Media Pvt Ltd
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3391838/ https://ncbi.nlm.nih.gov/pubmed/22787344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0974-2700.96483 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|